Navigation Links
Arterial Plaque Significantly Reduced in Women Age 50-59 Taking,Hormones, Says New Analysis of Women's Health Initiative Data

Fourth Study to Indicate that Early Use of Estrogen May be Cardio-Protective

PHOENIX, June 20, 2007 /PRNewswire-USNewswire/ -- A new analysis of Women's Health Initiative data published in the New England Journal of Medicine, shows significant reduction in calcified plaque for women aged 50 to 59 using hormone therapy (HT) compared with women taking a placebo. This is the first time the relationship between estrogen therapy and coronary artery calcium (CAC) has been evaluated in a randomized trial.

The amount of CAC is now well-recognized as a strong predictor of future heart attacks and other coronary events. Using cardiac CT scans, CAC was measured in 1064 WHI women. After adjustment for other coronary risk factors, the risks of having mild-to-moderate CAC were 20 to 30 percent lower and the risks of severe CAC were 40 percent lower in the group of women assigned to the active HT group compared to those receiving placebo. Even more impressive was the finding that mild-to-moderate CAC scores were 40 to 50 percent lower and severe CAC was 60 percent lower in those women who were actually taking their study medications regularly.

"This is the fourth peer-reviewed re-analysis of WHI data to suggest that estrogen may be cardio-protective for younger women," said Dr. S. Mitchell Harman, Director of the Kronos Longevity Research Institute (KLRI). The Institute is conducting the Kronos Early Estrogen Prevention Study (KEEPS), a randomized, controlled, double-blinded trial of 720 recently menopausal women at nine study centers across the United States. The KEEPS is designed to provide prospective data on the risks and benefits of early menopausal HT, particularly as it relates to the progression of atherosclerosis. "The new findings from the WHI continue to support the KEEPS hypothesis that hormones may be good early, but bad late," Dr. Harman said.

This latest study follows an April article in th e Journal of the American Medical Association, which found a 24 percent reduction in risk for coronary heart disease in women starting hormone therapy less than ten years after menopause. The JAMA study also found a 30 percent reduction in over-all deaths among women aged 50-59 using HT.

An earlier re-analysis of WHI data, summarized in articles in the Journal of Women's Health and the Archives of Internal Medicine in early 2006, also indicated that estrogen may be cardio-protective for younger women. The Women's Health Initiative was halted in July 2002 due to over-all elevated risks.

"These findings lend further support to the theory that estrogen may slow early stages of plaque build-up and lead to less 'hardening' of the arteries supplying blood flow to the heart," said Dr. JoAnn Manson, from Brigham and Women's Hospital in Boston. Dr. Manson is the lead physician who contributed to the "Estrogen Therapy and Coronary Artery Calcification" study. She is also the lead investigator for the KEEPS trial at the study center in Boston.

Interviews are available by the investigators at all nine KEEPS study centers:

    -- Albert Einstein College of Medicine of Yeshiva University/Montefiore

       Medical Center, Bronx, NY

    --  College of Physicians and Surgeons, New York, NY

    -- Harvard Medical School/Brigham and Women's Hospital, Boston, MA

    -- Kronos Longevity Research Institute, Phoenix, AZ

    -- Mayo Clinic College of Medicine, Rochester, MN

    -- University of California-San Francisco/Center for Reproductive Health,

       San Francisco, CA

    -- University of Utah School of Medicine, Salt Lake City, UT

    -- University of Washington School of Medicine, Seattle, WA

    -- Yale University College of Medicine, New Haven, CT

CONTACT: Lisa Hanna, +1-202-466-9633, , forKronos Longevity Research Institute lisa@turnerstrategies.com

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
2. REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis
3. Evidence of Nanoparticles Found in Plaque-Filled Arteries
4. CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries
5. CSL Therapy That Mimics Good Cholesterol May Reduce Plaque Volume in Coronary Arteries
6. Calcium Plaque Build-up in the Arteries Leads to Coronary Heart Disease in Multi-Ethnic Groups
7. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
8. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
10. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
11. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
Breaking Medicine Technology:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
Breaking Medicine News(10 mins):